JPS6231684B2 - - Google Patents

Info

Publication number: JPS6231684B2
Authority: JP; Japan
Prior art keywords: coenzyme; photosensitivity; hemolysis; animals; formulation example
Prior art date: 1977-12-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP52156706A

Other languages

English (en)

Japanese (ja)

Other versions

JPS5489036A (en

Inventor

Shuichi Kimura

Akihiko Isobe

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai Co Ltd

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-12-27

Filing date

1977-12-27

Publication date

1987-07-09

1977-12-27 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1977-12-27 Priority to JP15670677A priority Critical patent/JPS5489036A/ja

1979-07-14 Publication of JPS5489036A publication Critical patent/JPS5489036A/ja

1987-07-09 Publication of JPS6231684B2 publication Critical patent/JPS6231684B2/ja

Status Granted legal-status Critical Current

Links

ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 37
206010034972 Photosensitivity reaction Diseases 0.000 claims description 27
230000036211 photosensitivity Effects 0.000 claims description 27
235000017471 coenzyme Q10 Nutrition 0.000 claims description 18
241001465754 Metazoa Species 0.000 claims description 11
239000003795 chemical substances by application Substances 0.000 claims description 8
230000002265 prevention Effects 0.000 claims description 6
239000000203 mixture Substances 0.000 description 15
206010018910 Haemolysis Diseases 0.000 description 12
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
239000003814 drug Substances 0.000 description 12
238000009472 formulation Methods 0.000 description 12
230000008588 hemolysis Effects 0.000 description 11
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 7
229940079593 drug Drugs 0.000 description 7
-1 Nitsukol HCO Chemical class 0.000 description 6
235000014113 dietary fatty acids Nutrition 0.000 description 6
210000003743 erythrocyte Anatomy 0.000 description 6
239000000194 fatty acid Substances 0.000 description 6
229930195729 fatty acid Natural products 0.000 description 6
239000000843 powder Substances 0.000 description 6
229920002261 Corn starch Polymers 0.000 description 5
229920000168 Microcrystalline cellulose Polymers 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
239000008120 corn starch Substances 0.000 description 5
235000019813 microcrystalline cellulose Nutrition 0.000 description 5
239000008108 microcrystalline cellulose Substances 0.000 description 5
229940016286 microcrystalline cellulose Drugs 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
241000287828 Gallus gallus Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
235000013330 chicken meat Nutrition 0.000 description 3
239000005515 coenzyme Substances 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
239000012528 membrane Substances 0.000 description 3
125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 3
244000144977 poultry Species 0.000 description 3
235000013594 poultry meat Nutrition 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
229930002875 chlorophyll Natural products 0.000 description 2
235000019804 chlorophyll Nutrition 0.000 description 2
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
244000144972 livestock Species 0.000 description 2
238000000034 method Methods 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
208000017520 skin disease Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
239000003204 tranquilizing agent Substances 0.000 description 2
230000002936 tranquilizing effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
230000002407 ATP formation Effects 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
241000195649 Chlorella <Chlorellales> Species 0.000 description 1
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
206010015218 Erythema multiforme Diseases 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
235000019733 Fish meal Nutrition 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
235000019764 Soybean Meal Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000282887 Suidae Species 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
240000001085 Trapa natans Species 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003270 Vitamin B Natural products 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008122 artificial sweetener Substances 0.000 description 1
235000021311 artificial sweeteners Nutrition 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000004098 cellular respiration Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960002155 chlorothiazide Drugs 0.000 description 1
230000007665 chronic toxicity Effects 0.000 description 1
231100000160 chronic toxicity Toxicity 0.000 description 1
238000009535 clinical urine test Methods 0.000 description 1
239000011280 coal tar Substances 0.000 description 1
239000011436 cob Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000011257 definitive treatment Methods 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
BVEWMNTVZPFPQI-UHFFFAOYSA-N dialuric acid Chemical compound OC1C(=O)NC(=O)NC1=O BVEWMNTVZPFPQI-UHFFFAOYSA-N 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000027721 electron transport chain Effects 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000004467 fishmeal Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000007803 itching Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
238000003305 oral gavage Methods 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
239000003209 petroleum derivative Substances 0.000 description 1
NSFSLUUZQIAOOX-LDCXZXNSSA-N pheophorbide a Chemical compound N1C(C=C2[C@H]([C@H](CCC(O)=O)C(=N2)C2=C3NC(=C4)C(C)=C3C(=O)[C@@H]2C(=O)OC)C)=C(C)C(C=C)=C1C=C1C(C)=C(CC)C4=N1 NSFSLUUZQIAOOX-LDCXZXNSSA-N 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000004455 soybean meal Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
230000001732 thrombotic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
229940035936 ubiquinone Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
235000019156 vitamin B Nutrition 0.000 description 1
239000011720 vitamin B Substances 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1

Landscapes

Fodder In General (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP15670677A 1977-12-27 1977-12-27 Remedy and preventive for hypersensitivity to light Granted JPS5489036A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP15670677A JPS5489036A (en)	1977-12-27	1977-12-27	Remedy and preventive for hypersensitivity to light

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP15670677A JPS5489036A (en)	1977-12-27	1977-12-27	Remedy and preventive for hypersensitivity to light

Publications (2)

Publication Number	Publication Date
JPS5489036A JPS5489036A (en)	1979-07-14
JPS6231684B2 true JPS6231684B2 (fr)	1987-07-09

Family

ID=15633549

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP15670677A Granted JPS5489036A (en)	1977-12-27	1977-12-27	Remedy and preventive for hypersensitivity to light

Country Status (1)

Country	Link
JP (1)	JPS5489036A (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH078977Y2 (ja) *	1989-11-08	1995-03-06	新日軽株式会社	空調機を有するユニット窓枠
WO1998001039A1 (fr) *	1996-07-08	1998-01-15	Idemitsu Materials Co., Ltd.	Composition d'alimentation pour volaille
WO1998051164A1 (fr) *	1997-05-14	1998-11-19	Idemitsu Petrochemical Co., Ltd.	Composition alimentaire pour poulets et procede d'alimentation associe

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS57120519A (en) *	1981-01-19	1982-07-27	Takeda Chem Ind Ltd	Preventing agent and remedy for disease caused by srs-a
JPS57128624A (en) *	1981-02-02	1982-08-10	Takeda Chem Ind Ltd	Preventive and remedy for disease caused by srs-a
IT1157269B (it) *	1982-03-19	1987-02-11	Seuref Ag	Nuove formulazioni farmaceutiche contenenti il coenzima q10 adatte per la somministrazione topica
JPS61289029A (ja) *	1985-06-11	1986-12-19	Shiseido Co Ltd	抗色素沈着剤
TW200304372A (en) *	2002-03-20	2003-10-01	Kanegafuchi Chemical Ind	Compositions for diabetes
JP6249415B2 (ja) *	2012-09-03	2017-12-20	学校法人北里研究所	新規光線過敏症抑制剤トレハンジェリン物質及びその製造法

1977
- 1977-12-27 JP JP15670677A patent/JPS5489036A/ja active Granted

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH078977Y2 (ja) *	1989-11-08	1995-03-06	新日軽株式会社	空調機を有するユニット窓枠
WO1998001039A1 (fr) *	1996-07-08	1998-01-15	Idemitsu Materials Co., Ltd.	Composition d'alimentation pour volaille
WO1998051164A1 (fr) *	1997-05-14	1998-11-19	Idemitsu Petrochemical Co., Ltd.	Composition alimentaire pour poulets et procede d'alimentation associe
US6251442B1 (en) *	1997-05-14	2001-06-26	Idemitsu Petrochemical Co., Ltd.	Feed composition for broilers and method for breeding broilers

Also Published As

Publication number	Publication date
JPS5489036A (en)	1979-07-14

Publication	Publication Date	Title
Trown et al.	1976	Inhibition of growth and regression of a transplantable rat chondrosarcoma by three retinoids
EP0083775B1 (fr)	1989-09-13	Compositions d'acide 5-aminosalicylique à bonne solubilité
JPH0283326A (ja)	1990-03-23	原虫感染症治療用組成物
JPH10109933A (ja)	1998-04-28	医薬組成物
TW200843725A (en)	2008-11-16	Organic compounds
CA2999030C (fr)	2019-10-29	Compositions pharmaceutiques renfermant du palmitoylethanolamide et des inhibiteurs d'hydrolase d'amides d'acide gras naturels et leur utilisation dans le traitement de douleur neuropathique
US11931342B2 (en)	2024-03-19	Magnesium biotinate compositions and methods of use
US3634583A (en)	1972-01-11	Pharmaceutical composition for the treatment of oedematous conditions and hypertension
US5916925A (en)	1999-06-29	Pharmaceutical composition for treatment of dementia
JPS6231684B2 (fr)	1987-07-09
US20050154066A1 (en)	2005-07-14	Antiaging composition
AU2005204044B2 (en)	2010-07-22	Antiaging composition
JPH0148247B2 (fr)	1989-10-18
JPS6313967B2 (fr)	1988-03-29
JPH0133082B2 (fr)	1989-07-11
EP0495106B1 (fr)	1995-12-06	Promoteur d'osteogenese
US20200237710A1 (en)	2020-07-30	Synergistic composition of vitamin c and vitamin k1, and compositions thereof for the treatment of cancer
US2893914A (en)	1959-07-07	Thiadicarbocyanine anthelmintic compositions and methods of using them
AU2009297562B2 (en)	2015-04-23	Agent for preventing and/or treating functional gastrointestinal disorder
JPH07330593A (ja)	1995-12-19	疲労改善剤
BR112019016778A2 (pt)	2020-03-31	Composição farmacêutica compreendendo ácido 2,5- dihidrobenzenosulfônico ou um dos seus sais farmacêuticos aceitáveis sob forma de unidades de fornecimento individualizadas e seu método de fabricação
WO2008065339A1 (fr)	2008-06-05	Composition pharmaceutique de mémantine
CN107648307B (zh)	2021-06-04	一种组合物、其制备方法和应用
JPS60139618A (ja)	1985-07-24	白内障治療薬
US3803319A (en)	1974-04-09	Treating hyperlipemia with isatin